ERYTHROPOIETIN STUDY

Feasibility and safety of erythropoietin (EPO) administration in patients with acute myocardial infarction (AMI) to improve cardiac function and remodelling.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000238572

Enrollment

Registered

2006-06-14

Start date

2006-06-07

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to test the feasibility and safety of intravenous erythropoietin (EPO) injections in patients with recent acute myocardial infarction to improve cardiac remodelling and cardiac function

Interventions

Erythropoietin administration (10000units given as a one-off [single dose] intravenous bolus dose) within 24 hours of primary percutaneous intervention to treat patients with AMI. As this is a phase I safety study all subjects will receive open-label erythropoietin and there will be no control group or comparitor.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Acute ST elevation myocardial infarction that are treated with primary angioplasty and stenting who have significant left ventricular (LV) impairment.

Exclusion criteria

Multiple - but particularly major comorbidities.

Outcome results